AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS
申请人:ETERNITY BIOSCIENCE INC.
公开号:US20170152264A1
公开(公告)日:2017-06-01
The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.